Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
about
Adoptive immunotherapy for cancer: building on successFocus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human gliomaAdoptive T cell therapy for cancer in the clinicPeritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC)Immunologic aspect of ovarian cancer and p53 as tumor antigen.Non-small cell lung cancer: current treatment and future advancesImmune Checkpoint Modulators: An Emerging Antiglioma ArmamentariumNatural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor ActivityCurcumin and tumor immune-editing: resurrecting the immune systemMyeloid suppressor cells and immune modulation in lung cancerStrategies and Advancements in Harnessing the Immune System for Gastric Cancer ImmunotherapyVaccines for pancreatic cancerLung cancer: a classic example of tumor escape and progression while providing opportunities for immunological interventionNovel immunotherapeutic strategies of gastric cancer treatmentLung cancer vaccinesTumor infiltrating lymphocytes in ovarian cancerT-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumorsDistinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cellsFocus on Nivolumab in NSCLCLung cancer vaccines: current status and future prospectsRegulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+ T cell immune response by the cytokine TGFbetaA pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastomaTargeting myeloid-derived suppressor cells augments antitumor activity against lung cancer.Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence.Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factorsEvaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases.Interleukin-7 and Immunosenescence.The Treg/Th17 paradigm in lung cancerSelective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancerInfiltrative T regulatory cells in enucleated uveal melanomas.The role of regulatory T cells in cancer.Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg).Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunityVaccines against human carcinomas: strategies to improve antitumor immune responses.Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.Evaluation of Apoptotic Marker Bcl2, CD4+, Human Hepatocyte Growth Factor and Metalloproteinase-9 as Tumor Markers for Patients with Hepatocellular Carcinoma.Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance.Stroma-derived Fibrinogen-like Protein 2 Activates Cancer-associated Fibroblasts to Promote Tumor Growth in Lung Cancer
P2860
Q24546258-8F1914DC-DDA7-4892-8EA5-7B03DAB27016Q24615166-2F8FA210-734B-4F63-BADF-09D409C8026AQ24680405-6A1744C6-6400-4670-A38C-113DFDCBFFE8Q24804586-2F1D50A0-1007-4138-AF65-EDA84D56F107Q24814703-DBB5A911-A201-488B-95C5-0E1FD4471200Q26740333-1CE1FC67-F579-46E4-9C96-68362EDBA3F0Q26765459-C4EB01EC-2BAF-403B-AA1E-A93E34E3CC3BQ26773135-2D51B1AD-3C8D-4E55-9568-C0E749E05202Q26783491-43F1BC62-7BF0-48AE-B626-3B1E91978384Q26823251-6759A0CC-64C8-4A79-817B-8E2CD70A8322Q26823515-F477B489-3A92-4521-9B73-7D3899E498F3Q26825850-69F03C25-D7C2-4C6B-A6E6-2536F241CB55Q26850218-8C55E3AE-7085-4C88-B805-736E406E2C98Q27011232-926A7156-C3B1-4F25-9588-DFED9BE9AE8AQ27014375-5B3747E8-ECAF-4AD9-8AAE-54387E6E88B4Q27021878-7D30DD4D-C38A-4BAF-ACB3-3EDE0715334BQ27335110-C7FD52E4-6DDB-4C7D-B914-6B4500A9C6BDQ27350034-A6D1B849-69F8-425B-ABF9-554BC8D9E1B0Q27438176-EFB21775-1F15-40FF-9074-2873D5D755C3Q28073759-3EAE720D-F3FF-448A-83DE-A654CCDBA868Q28080849-F8D0E41C-7E96-4263-8294-127AECCBA18AQ28475223-465E33D2-7D3F-4100-92C7-2A414D23970BQ28731711-3D91A727-F63C-43EE-8FAF-6F64D8D4D4D8Q30413623-13577513-294A-45B5-8093-7A3F902792EEQ30542070-FC8529C9-B2EE-4613-B890-507B3A642FE1Q33377058-81F4EDFB-89E9-4838-A10E-026B418D15CBQ33488520-22289B4F-75BE-4F76-B1C3-E2B942596DBCQ33537482-B3D4F939-761F-47AD-A53E-DE8B7CD9DF84Q33582101-119630AB-CEC8-45A9-92B3-59D7AAFAD45AQ33608606-058A8969-A850-4192-A369-50E9CBBA2848Q33608626-064447EA-C4A6-4E27-A906-CBC267AEB436Q33623491-41426FD2-10BF-46F0-94DA-907B7DADB4ABQ33631986-EF382B64-5862-498B-AA72-FBB04D5CC83CQ33641504-3D26E397-86A4-419E-8B11-2E946292D0E5Q33657130-4FC27154-0B85-4B27-B487-AE11C77FB3A9Q33734281-514E917A-7AB6-477A-B0E5-26540A0AB601Q33754724-B6A0AC08-C957-4DC8-BC27-658231565BF3Q33774580-036DF5D5-CDEB-4BDE-9B22-B96DB7BCBB12Q33822831-21A3EF72-2FD6-45E4-ACC6-5B7758BE52A5Q33837289-FE105CDF-7567-4D19-8A66-4C6990F2E4A2
P2860
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Regulatory CD4
@nl
Regulatory CD4(+)CD25(+) T cel ...... and late-stage ovarian cancer.
@ast
Regulatory CD4(+)CD25(+) T cel ...... and late-stage ovarian cancer.
@en
type
label
Regulatory CD4
@nl
Regulatory CD4(+)CD25(+) T cel ...... and late-stage ovarian cancer.
@ast
Regulatory CD4(+)CD25(+) T cel ...... and late-stage ovarian cancer.
@en
prefLabel
Regulatory CD4
@nl
Regulatory CD4(+)CD25(+) T cel ...... and late-stage ovarian cancer.
@ast
Regulatory CD4(+)CD25(+) T cel ...... and late-stage ovarian cancer.
@en
P2093
P1433
P1476
Regulatory CD4(+)CD25(+) T cel ...... and late-stage ovarian cancer
@en
P2093
Schlienger K
P304
P407
P577
2001-06-01T00:00:00Z